SCHEMBL16213205

SCHEMBL16213205

Cn1cc(-c2nn(C(c3ccccc3)(c3ccccc3)c3ccccc3)c3cc4[nH]c(=O)ccc4cc23)cn1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.58
AXL P30530 8/20 0.39
EPHX2 P34913 1/20 0.38
PIM1 P11309 1/20 0.36
TYRO3 Q06418 4/20 0.36
MERTK Q12866 3/20 0.36
CREBBP Q92793 2/20 0.35
BRD4 O60885 2/20 0.35
EP300 Q09472 1/20 0.35
CECR2 Q9BXF3 1/20 0.35
BRD9 Q9H8M2 1/20 0.35
METAP2 P50579 1/20 0.34
MET P08581 1/20 0.34
NPBWR1 P48145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16213407 0.81 MAPK1 (0.57) MAPK1
SCHEMBL16620153 0.77 MAPK1 (0.37) MAPK1
SCHEMBL16213597 0.77 F11 (0.38) MAPK1
SCHEMBL16213305 0.75 MAPK1 (0.57) MAPK1AXLTYRO3MERTKCREBBP
SCHEMBL14895564 0.74 TYRO3 (0.43) AXLPIM1TYRO3MERTK
SCHEMBL16224857 0.74 MAPK1 (1.00) MAPK1AXLPIM1
SCHEMBL16213287 0.73 L3MBTL1 (0.40) AXLTYRO3MERTKCREBBPBRD4
SCHEMBL16213579 0.73 MAPK1 (0.55) MAPK1
SCHEMBL16213241 0.70 FGFR4 (0.40) MAPK1TYRO3
SCHEMBL23211013 0.68 KDM4E (0.40) AXLPIM1TYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759805-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2020-09-01 US disclosed
EP-2991654-B1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2018-11-21 EP disclosed
US-20180319804-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-11-08 US disclosed
US-10065967-B2 Compounds that are ERK inhibitors Merck, Sharp & Dohme Corp. (US) 2018-09-04 US disclosed
US-20170320882-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-9745307-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-29 US disclosed
US-20160068532-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-03-10 US disclosed
EP-2991654-A2 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-03-09 EP disclosed
WO-2014179154-A2 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759805-B2 Compounds that are ERK inhibitors MAPK1, MAPK4, MAP3K1 MAPK1 1/4885AXL 1739/4885EPHX2 2590/4885
US-20180319804-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 MAPK1 1/4885AXL 1405/4885EPHX2 2787/4885
US-20170320882-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 MAPK1 1/4885AXL 1405/4885EPHX2 2787/4885
US-10065967-B2 Compounds that are ERK inhibitors MAPK1, MAPK4, MAP3K1 MAPK1 1/4885AXL 1739/4885EPHX2 2590/4885
US-20160068532-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAP3K20, MAPK6 MAPK1 1/4885AXL 798/4885EPHX2 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.